反义和RNAi疗法市场－全球产业规模、份额、趋势、机会和预测，按技术、应用、给药途径、地区和竞争格局划分，2020-2030年预测

2024年全球反义寡核苷酸和RNA干扰疗法市场规模为52亿美元，预计2030年将以19.19%的复合年增长率成长至149.1亿美元。反义寡核苷酸和RNA干扰疗法属于分子药物，它们透过反义寡核苷酸抑制蛋白质合成或透过RNA干扰降解信使RNA，精确调控基因表达，为多种疾病提供标靶治疗。该市场的成长主要受全球遗传性和慢性疾病发病率上升以及对复杂分子疾病机制的深入理解的推动，这使得高度特异性的治疗设计成为可能。研发投入的不断增加进一步推动了这一成长，为治疗选择有限的疾病提供了更多治疗选择。

主要市场驱动因素

全球反义和RNAi疗法市场受到遗传性和慢性疾病负担日益加重的显着影响，这凸显了对创新疗法的巨大未满足医疗需求。这些疗法能够精准调控基因表达，从而解决许多传统疗法难以发挥作用的疾病的根本原因。

主要市场挑战

将核酸分子高效、精准地标靶递送至特定细胞和组织这一难题持续存在，直接阻碍了全球反义和RNAi疗法市场的成长。这项挑战源自于这些分子的固有特性，例如其体积、负电荷以及易受酶降解等，这些特性阻碍了它们穿过生物屏障并以足够浓度到达细胞内靶点。

主要市场趋势

反义和RNAi疗法正日益扩大至罕见疾病以外的更广泛治疗领域。这种策略多元化包括针对更常见的慢性疾病，例如心血管疾病、代谢性疾病和神经系统疾病，这表明人们对该技术在更广泛患者群体中的适用性越来越有信心。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球反义与RNAi疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过技术手段（RNA干扰、反义RNA）
  • 依给药途径（静脉注射、鞘内注射、皮下注射、其他）
  • 依应用领域（眼科、心血管代谢及肾臟疾病、癌症、呼吸系统疾病、皮肤病、神经退化性疾病、遗传性疾病、传染病）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美反义与RNAi疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲反义与RNAi疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区反义与RNAi疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲反义和RNAi疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲反义与RNAi疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球反义和RNAi疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Olix Pharmaceuticals, Inc.
• GSK plc
• Sanofi Aventis SA
• Alnylam Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Benitec Biopharma Inc
• Silence Therapeutics Inc.
• Arbutus Biopharma Inc.
• Sarepta Therapeutics Inc.
• Percheron Therapeutics Limited.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Antisense And RNAi Therapeutics Market, valued at USD 5.20 Billion in 2024, is projected to experience a CAGR of 19.19% to reach USD 14.91 Billion by 2030. Antisense and RNAi therapeutics represent a molecular medicine class that precisely modulates gene expression by either inhibiting protein production via antisense oligonucleotides or degrading messenger RNA through RNA interference, offering targeted interventions for various diseases. The market's expansion is fundamentally driven by the rising global incidence of genetic and chronic disorders, alongside a burgeoning understanding of intricate molecular disease mechanisms enabling highly specific therapeutic design. Growing investments in research and development further propel this growth by expanding the addressable therapeutic landscape for conditions with limited treatment options.

Key Market Drivers

The global Antisense and RNAi Therapeutics Market is significantly influenced by the increasing burden of genetic and chronic diseases, which establishes a profound unmet medical need for innovative treatments. These therapies offer precise modulation of gene expression, addressing the root causes of many disorders where conventional treatments fall short. The substantial patient population suffering from these conditions drives consistent demand for novel therapeutic avenues.

Key Market Challenges

The persistent complexity in achieving efficient and precisely targeted *in vivo* delivery of nucleic acid-based molecules to specific cells and tissues directly impedes the growth of the Global Antisense and RNAi Therapeutics Market. This challenge arises from the inherent properties of these molecules, such as their size, negative charge, and susceptibility to enzymatic degradation, which hinder their ability to cross biological barriers and reach their intracellular targets in sufficient concentrations. Consequently, the development of novel therapies is prolonged due to the extensive research required for suitable delivery vehicles, increasing overall development costs and time to market.

Key Market Trends

Antisense and RNAi therapeutics are increasingly expanding into broader therapeutic areas beyond rare diseases. This strategic diversification involves targeting more prevalent chronic conditions such as cardiovascular, metabolic, and neurological disorders, indicating a growing confidence in the technology's applicability to larger patient populations.

Key Market Players

• Olix Pharmaceuticals, Inc.
• GSK plc
• Sanofi Aventis S.A.
• Alnylam Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Benitec Biopharma Inc
• Silence Therapeutics Inc.
• Arbutus Biopharma Inc.
• Sarepta Therapeutics Inc.
• Percheron Therapeutics Limited.

Report Scope:

In this report, the Global Antisense And RNAi Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antisense And RNAi Therapeutics Market, By Technology:

• RNA Interference
• Antisense RNA

Antisense And RNAi Therapeutics Market, By Route of Administration:

• Intravenous Injections
• Intrathecal Injections
• Subcutaneous Injections
• Other

Antisense And RNAi Therapeutics Market, By Application:

• Ocular
• Cardiometabolic & Renal Disorders
• Cancer
• Respiratory Disorders
• Skin Diseases
• Neurodegenerative Disorders
• Genetic Disorders
• Infectious Diseases

Antisense And RNAi Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antisense And RNAi Therapeutics Market.

Available Customizations:

Global Antisense And RNAi Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antisense And RNAi Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (RNA Interference, Antisense RNA)
  • 5.2.2. By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other)
  • 5.2.3. By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Antisense And RNAi Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Route of Administration
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antisense And RNAi Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Antisense And RNAi Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Antisense And RNAi Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Application

7. Europe Antisense And RNAi Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Route of Administration
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antisense And RNAi Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Application
  • 7.3.2. France Antisense And RNAi Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Antisense And RNAi Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Antisense And RNAi Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Antisense And RNAi Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Application

8. Asia Pacific Antisense And RNAi Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antisense And RNAi Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Application
  • 8.3.2. India Antisense And RNAi Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Antisense And RNAi Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Antisense And RNAi Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Antisense And RNAi Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Application

9. Middle East & Africa Antisense And RNAi Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Route of Administration
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antisense And RNAi Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Antisense And RNAi Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Antisense And RNAi Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Application

10. South America Antisense And RNAi Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Route of Administration
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antisense And RNAi Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Antisense And RNAi Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Antisense And RNAi Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antisense And RNAi Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Olix Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GSK plc
• 15.3. Sanofi Aventis S.A.
• 15.4. Alnylam Pharmaceuticals, Inc.
• 15.5. Ionis Pharmaceuticals, Inc.
• 15.6. Benitec Biopharma Inc
• 15.7. Silence Therapeutics Inc.
• 15.8. Arbutus Biopharma Inc.
• 15.9. Sarepta Therapeutics Inc.
• 15.10. Percheron Therapeutics Limited.

16. Strategic Recommendations

17. About Us & Disclaimer